Letermovir
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Letermovir: From Cytomegalovirus (CMV) Infection to Vulvovaginal Candidiasis
One-Sentence Summary
Letermovir is an antiviral drug highly specific to cytomegalovirus (CMV), acting as a terminase complex inhibitor; this evidence pack does not contain a recorded original indication or licensed use. TxGNN predicts it may be effective for Vulvovaginal Candidiasis, but this direction is currently supported by 0 clinical trials and 0 publications, and the drug's own mechanistic profile argues against pharmacological plausibility — this is most likely a model-level false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack |
| Predicted New Indication | Vulvovaginal Candidiasis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 (model prediction only) |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The formal original_moa field for letermovir is not populated in this evidence pack, but the model's own rationale describes its mechanism: letermovir is a highly specific inhibitor of the CMV DNA terminase complex (UL56/UL89/UL51). Its antiviral activity is confined to the Herpesviridae family, particularly CMV, and it does not act on any known fungal target — such as ergosterol synthesis or glucan synthase — that would be relevant to Candida species.
Vulvovaginal candidiasis is a fungal infection with a biology entirely unrelated to viral DNA packaging. There is no known pharmacological pathway connecting a CMV terminase inhibitor to antifungal activity, and no clinical or preclinical evidence in this pack links letermovir to any fungal indication.
Given this mismatch, the high TxGNN confidence score (99.88%) most plausibly reflects a spurious association in the knowledge-graph embedding space rather than a genuine pharmacological signal. The absence of the drug's original indication and confirmed MOA in structured form (flagged as gaps DG001/DG002) further limits the ability to validate or refute this link with confidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Taiwan Market Information
Letermovir is not currently marketed in Taiwan, and no drug licenses were found for this product (0 authorizations on record).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only) with zero supporting clinical trials or literature, and the drug's own mechanism of action — a CMV-specific antiviral terminase inhibitor — is not pharmacologically consistent with an antifungal indication. This pattern is consistent with a knowledge-graph false positive rather than a credible repurposing signal.
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank (DG002)
- Original indication and regulatory history for letermovir
- Any preclinical or in vitro data testing antifungal activity, if such data exists, to either support or close out this signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.